

Certara Strategic Early Development Solutions


Expert Support at Every Stage from Candidate Selection through Phase 1 Completion

Successfully navigating the challenges of moving from candidate selection to successful Phase I completion requires significant expertise in drug development. Pharmaceutical development poses unique challenges due to its high cost, long duration and high attrition. Ensuring your therapy takes the optimal approach throughout early development is critical. Success in early development allows you to unlock funding and partnership opportunities and sets you up for success in later phases.

Derisk & Streamline Your Early Development Framework

Designed based on experience from hundreds of early development projects and clients across multiple indications and therapeutic areas, Certara has created a flexible early development model that supports you through the first two years. By streamlining your operational model and derisking your dependence on individual consultants, Certara delivers a faster, more agile framework for executing early development research.


Typical start-up early development model



Current Model Challenges

- Lack of full control and visibility to project timelines
- Multiple points of failure
- Complex communication management, information flow
- Lower productivity

A new paradigm with Certara




Benefits

- One point of contact
- Flexible and scalable model
- Strategic development
- Expert resources with thousands of years combined experience in end-to-end drug development that work as a team

How it works: Designed with You in Mind

Certara’s cross-functional team members flex in and out based on your needs, with a dedicated program lead – ensuring continuous, scalable coverage.



Why Certara? We are global leaders with a proven record of success in early development.

>90%

all novel drugs approved by the US FDA since 2014 were supported by Certara services or technology

30+

new biotech companies onboarded in H1 2024

250+

biotech companies supported in H1 2024

400+

MD, PharmD, and PhD drug development scientists


7

of Certara’s scientists are recognized as top 2% most cited



Certara's early development team members flex in and out as your program evolves – ensuring continuous, scalable coverage

Illustrative example: Certara team size can flex depending on your team and program's needs



Underpinned by Certara's industry-leading technology and software

Questions? Contact any one of our experts for a complimentary consultation to learn how Certara can help your early development program today!



Dr. Fran Brown

Senior Vice President,
Certara Drug Development
Solutions,
Fran.Brown@certara.com

30+ years of experience with strategic and operational drug development from early discovery to filing and post-marketing.



Dr. David Mitchell

Senior Vice President,
Certara Drug Development
Solutions,
Dave.Mitchell@certara.com

30+ years in clinical pharmacology, project leadership, and strategic drug development.



Kevin Hershberger

Vice President,
Certara Drug Development
Solutions,
Kevin.Hershberger@certara.com

25+ years of pharma project leadership and cross-functional program management experience.

Contact **Ashley.Schwalje@certara.com**
to discuss your early development program needs today.
www.certara.com/early-development



Our mission

We use biosimulation, data, regulatory, and scientific expertise to transform drug development and accelerate medicines to patients.

Continuously investing in the future of technology, enabling partners to focus on the science and lead in innovation.



Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. For more information visit certara.com